Long-term registry of adults with generalized myasthenia gravis treated with C5 inhibitors
Collects long-term data on safety and outcomes in adults with generalized myasthenia gravis.
Key facts
- Who runs it
- Alexion Pharmaceuticals, Inc.
- Where
- Abhā, Jeddah, and Riyadh, Saudi ArabiaSee the 3 sitesAlso in 6 other countries, 47 sites
- Trial code
- Registry title
- Registry of Participants With Generalized Myasthenia Gravis Treated With Alexion C5 Inhibition Therapies (C5ITs)
- Status
- Recruiting
- People taking part
- 500 people, planned
- Started
- 2 Dec 2019
- Expected to end
- 1 Oct 2029
- Type of study
- Observational
- Record updated
- 18 February 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The registry is looking for adults with generalized myasthenia gravis who are treated with, or were previously treated with, an Alexion C5 inhibitor therapy such as Soliris or Ultomiris.
- Age
- 18 Years or older
- Sex
- All sexes can join.
- Disease stage
- Diagnosis of generalized myasthenia gravis (gMG).
- Earlier treatment
- Must be treated with Alexion C5 inhibitor therapy at enrollment. People treated earlier with Soliris or Ultomiris and then taken off it can also join.
Main reasons for not taking part
- Currently taking part in an Alexion-sponsored interventional clinical study for gMG treatment
- Cannot give signed informed consent
- No myasthenia gravis historical data available, such as MG-ADL and MGFA class
The registry criteria, word for word
Show all 4 criteriaShow less
Who can take part
- Participants with a diagnosis of gMG who are treated with Alexion C5IT at the time of enrollment, including patients previously treated with Soliris or Ultomiris and withdrawn from treatment
- Capable of giving signed informed consent, which includes compliance with the protocol requirements and restrictions
- Participants must have myasthenia gravis historical data, such as MG-ADL and MGFA class, available to be enrolled in the Registry
Who cannot take part
- Participants currently enrolled in an Alexion-sponsored interventional clinical study for treatment of gMG cannot be enrolled in the Alexion gMG Registry while enrolled/participating in the clinical study for gMG therapy
Where in Saudi Arabia
Also in 6 other countries, 47 sites
- AbhāHospital not named in the registryContact: Alexion Pharmaceuticals, Inc. (Sponsor)Taking people
- JeddahHospital not named in the registryContact: Alexion Pharmaceuticals, Inc. (Sponsor)Taking people
- RiyadhHospital not named in the registryContact: Alexion Pharmaceuticals, Inc. (Sponsor)Taking people
About the trial
What the trial wants to find out
Long-term, multicenter, multinational, observational, registry of patients with gMG that is designed to collect data on clinical outcomes and safety in patients prescribed Alexion C5 inhibitor therapies (C5IT) such as eculizumab (Soliris®) and ravulizumab (Ultomiris®).
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Long-Term, Observational, Global Registry of Patients With Generalized Myasthenia Gravis Who Have Received Treatment With Complement C5 Inhibition Therapies (C5ITs)
- Plain-language title
- Long-term registry of adults with generalized myasthenia gravis treated with C5 inhibitorsGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 18 February 2026